Screener
Sana Biotechnology SANA Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $2,123 | $1,669 |
| Accrued compensation | 7,584 | 13,240 |
| Accrued expenses and other current liabilities | 8,124 | 8,679 |
| Operating lease liabilities | 14,878 | 14,938 |
| Contingent consideration | 53,556 | 40,200 |
| Total current liabilities | 86,265 | 78,726 |
| Operating lease liabilities, net of current portion | 60,450 | 63,924 |
| Contingent consideration, net of current portion | 80,907 | 83,518 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's operating lease liabilities (current)?
- Sana Biotechnology (SANA) reported operating lease liabilities (current) of $14.88M in Q1 2026.
- How has Sana Biotechnology's operating lease liabilities (current) changed year-over-year?
- Sana Biotechnology's operating lease liabilities (current) increased by 14.4% year-over-year, from $13M to $14.88M.
- What is the long-term trend for Sana Biotechnology's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Sana Biotechnology's operating lease liabilities (current) has grown at a 32.1% compound annual growth rate (CAGR), from $3.71M to $14.94M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Sana Biotechnology's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude